Physician profile

Goran Topalo

Dentist · Palatine, IL

NPI 1164700324

$403.01

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$186.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nobel Biocare USA $155.93 2019-2023 Nobelactive
Straumann USA LLC $50.00 2019
Biohorizons Implant Systems INC. $45.05 2024 Biohorizons
Dentsply Sirona INC $38.02 2019-2024 Cavitron
3m Company $35.52 2019-2022
Peter Brasseler Holdings, LLC $19.67 2020
Align Technology, INC. $15.00 2022
Colgate Oral Pharmaceuticals, INC. $14.83 2024
Orapharma, A Division of Bausch Health US, LLC $14.56 2019
Solventum Corporation $14.43 2024 Vanish

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Goran Topalo

$403.01

in general payments reported 2019-2025

Years
2019-2024
Top company
Nobel Biocare USA

https://glasscript.com/doctor/52295/goran-topalo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.